Introduction

The prevalence of oncogenic driver mutations in early-stage resectable non-small-cell lung cancer (rNSCLC) in Malaysia remains unknown. This information may guide treatment decisions, especially tyrosine kinase inhibitor (TKI) use. We characterised the genomic landscape of early-stage NSCLC in a surgical cohort and explored its impact on TKI administration, particularly osimertinib.

Materials and methods

146 patients who underwent curative resection for early-stage rNSCLC were included in this study. Real-time polymerase chain reaction (PCR) and nextgeneration sequencing (NGS) were used to identify genetic alterations in tumour samples. Associations between EGFR status and clinico-pathological characteristics were analysed using uni- and multivariate logistic regression.

Results

A majority of patients were female non-smokers of Chinese ethnicity with an incidental adenocarcinoma. EGFR mutations were detected in 62.3% (n=91) of patients, with 93.4% harbouring single-locus mutations, primarily in exons 19 and 21. Co-mutations occurred in 11% (n=10) of EGFRmutant cases, most frequently involving TP53, and less commonly CTNNB1, HER2/ErbB2, and PTEN. Six (6.6%) patients had multi-loci EGFR mutations. Female sex and higher tumour histological grade were independent predictors for EGFR mutations, while former/never smokers showed higher odds on univariate analysis. Among patients tested for PD-L1 (78.8%), 46.6% had negative expression (tumour proportion score <1%), with no correlation to EGFR status.

Conclusion

This is the first genomic molecular profiling study to report exclusively on early-stage NSCLC in Malaysia. The high prevalence of EGFR mutations observed, predominantly involved sensitizing mutations at exons 19 and 21, and was associated with the female sex, a non- smoking status, higher tumour grade, but not PD-L1 expression. Early reflex genomic testing is vital to guide biomarker-driven peri-operative treatment strategies for rNSCLC.

1. Zhang SL, Yi XF, Huang LT, Sun L, Ma JT, Han CB. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials. BMC Cancer 2023; 23(1): 719.
2. Rajadurai P, How SH, Liam CK, Sachithanandan A, Soon SY, Tho LM. Lung cancer in Malaysia. J Thorac Oncol 2020; 15(3): 31723.
3. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26(21): 3552-9.
4. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375(9722): 1267-77.
5. Liam CK, Wahid MI, Rajadurai P, Cheah YK, Ng TS. Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients. J Thorac Oncol 2013; 8(6): 766-72.
6. Rajadurai P, Yap NY, Mohamed Yousoof SB, Cheah YK. Mutational profiling of lung cancer using next generation sequencing: A Malaysian real-world clinical diagnostic experience. J Mol Pathol 2023; 4(1): 31-43.
7. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9(2): 154-62.
8. Melosky B, Kambartel K, Haentschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a metaanalysis. Mol Diagn Ther 2022; 26(1): 7-18.
9. Boustany Y, Laraqui A, El Rhaffouli H, Bajjou T, El Mchichi B, El Anaz H, et al. Prevalence and patterns of EGFR mutations in nonsmall cell lung cancer in the Middle East and North Africa. Cancer Control 2022; 29: 10732748221129464.
10. Ten Berge DM, Aarts MJ, Groen HJ, Aerts JG, Kloover JS. A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. Eur J Cancer 2022; 165: 195-204.
11. Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Gallegos LF, et al. Prevalence of EGFR mutations in patients with resected stages I to III NSCLC: results from the EARLY-EGFR study. J Thorac Oncol 2024; 19(10): 1449-59.
12. Rajadurai P, Cheah PL, How SH, Liam CK, Annuar MA, Omar N, et al. Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. Lung Cancer 2019; 136: 65-73.
13. Sachithanandan A, Razi AA, Krishnasamy S, Chan KM, Lam HY, Diong NC, et al. Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of earlystage resectable non-small cell lung cancer (NSCLC) in Malaysia. Transl Lung Cancer Res 2025; 14(7): 2403.
14. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med 2020; 383(18): 1711-23.
15. Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med 2023; 389(2): 137-47.
16. Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol 2021; 17(31): 4045-55.
17. He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, et al.  Neoadjuvant Osimertinib for Resectable EGFR-Mutated NonSmall Cell Lung Cancer. J Clin Oncol 2025; 43(26): 2875-87.
18. Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, et al. Adjuvant osimertinib versus placebo in completely resected stage IA2–IA3 EGFR-mutated NSCLC: ADAURA2. Clin Lung Cancer 2023; 24(4): 376-80.
19. Soo RA, de Marinis F, Han JY, Ho JC, Martin E, Servidio L, et al. TARGET: a phase II, open-label, single-arm study of 5-year adjuvant osimertinib in completely resected EGFR-mutated stage II to IIIB NSCLC post complete surgical resection. Clin Lung Cancer 2024; 25(1): 80-4.
20. Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, et al. The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res 2018; 24(5): 1038-47.
21. Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res 2017; 23(9): 2195-202.
22. Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V, et al. Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs. J Clin Med 2020; 9(4): 1047.
23. Zhao Y, Pan Y, Cheng C, Zheng D, Zhang Y, Gao Z, et al. EGFRmutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis. J Cancer Res Clin Oncol 2020; 146(7): 1781-9.
24. Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, et al. Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFRmutant lung cancer. J Thorac Oncol 2024; 19(2): 240-51.
25. Tan AC, Saw SPL, Chen J, Lai GGY, Oo HN, Takano A, Lau DPX et al. Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer. JCO Precis Oncol 2022; 6: e2200278.
26. Feng J, Hueniken K, Fan ZJ, Corke L, Leighl NB, Liu G, et al. P2. 09-28 Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2023; 18(11): S343-4.
27. Bergethon K, Shaw AT, Ignatius Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30(8): 863-70.
28. Park E, Choi YL, Ahn MJ, Han J. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers. Pathol Res Pract 2019; 215(7): 152441.
29. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27(26): 4247-53.
30. Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in resected ALK-positive non–small-cell lung cancer. N Engl J Med 2024; 390(14): 1265-76.
31. Lee JM, Toloza EM, Pass HI, Johnson BE, Heymach JV, Sholl L, et al. P2. 01-06 NAUTIKA1 study: preliminary efficacy and safety data with neoadjuvant alectinib in patients with stage IB-III ALK+ NSCLC. J Thorac Oncol 2023; 18(11): S297-8.
32. Yang F, Yan X, Zhao H, Chu Q, Fan J, Liu H, et al.  179TiP: Lorlatinib as neoadjuvant treatment in stage IB-IIIB ALKrearranged non-small cell lung cancer (NEOLORA). J Thorac Oncol 2025; 20(3): S120.
33. Kim IA, Hur JY, Kim HJ, Lee SA, Hwang JJ, Kim WS, et al. Targeted next-generation sequencing analysis predicts the recurrence in resected lung adenocarcinoma harboring EGFR mutations. Cancers 2021; 13(14): 3632.
34. Kim Y, Ahn B, Yoon S, Lee G, Kim D, Chun SM, et al. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma. PLoS One 2023; 18(6): e0287256.
35. Saleh MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, Ulmer B, Wolf J, et al.  Comprehensive analysis of TP53 and KEAP1 mutations and their impact on survival in localized-and advanced-stage NSCLC. J Thorac Oncol 2022; 17(1): 76-88.
36. Ferrara MG, Martini M, D’Argento E, Forcella C, Vita E, Di Noia V, et al. PTEN loss as a predictor of tumor heterogeneity and poor prognosis in patients with EGFR-mutant advanced non–smallcell lung cancer receiving tyrosine kinase inhibitors. Clin Lung Cancer 2021; 22(4): 351-60.
37. Kimman M, Jan S, Kingston D, Monaghan H, Sokha E, Thabrany H, et al. Socioeconomic impact of cancer in member countries of the Association of Southeast Asian Nations (ASEAN): the ACTION study protocol. Asian Pac J Cancer Prev 2012; 13(2): 421-5.
38. How SH, Liam CK, Zainal Abidin MA, Hasbullah HH, Tho LM, Ho GF, et al. Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia. Cancer Manag Res 2022; 14: 1995-2005.